FDA advisory panel makes favorable recommendation for ARZERRA (ofatumumab)
17y agoen
From the article
GSK & GEN announced that FDA voted 10:3 that ofatumumab, reasonably likely to predict clinical benefit for patients with chronic CLL.
Continue reading on GSKYou might also wanna read
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
clinicaltrials.gov·7d ago
A Study to Investigate GSK5733584 as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)
clinicaltrials.gov·3d ago
Real-world data point to patient experience as next battleground for anti-CD20 therapies in RMS, says GlobalData
globaldata.com·6d ago
Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia
clinicaltrials.gov·1d ago
Real-World EV Plus Pembro Success Seen in Urothelial Cancer
Medscape·1d ago
A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia
clinicaltrials.gov·19h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.